These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1966 related articles for article (PubMed ID: 33686787)
1. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
3. Application of PD-1 Blockade in Cancer Immunotherapy. Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619 [TBL] [Abstract][Full Text] [Related]
4. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
6. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G Front Immunol; 2021; 12():637146. PubMed ID: 34025646 [TBL] [Abstract][Full Text] [Related]
7. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
8. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431 [TBL] [Abstract][Full Text] [Related]
9. CD155/TIGIT, a novel immune checkpoint in human cancers (Review). Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677 [TBL] [Abstract][Full Text] [Related]
10. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry. Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817 [TBL] [Abstract][Full Text] [Related]
11. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer. Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G Front Immunol; 2023; 14():1298524. PubMed ID: 38187388 [TBL] [Abstract][Full Text] [Related]
12. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy. Mu Y; Guan X Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504 [TBL] [Abstract][Full Text] [Related]
13. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141 [TBL] [Abstract][Full Text] [Related]
14. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J Front Immunol; 2021; 12():699895. PubMed ID: 34367161 [TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
16. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969 [TBL] [Abstract][Full Text] [Related]
17. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF Front Immunol; 2018; 9():2821. PubMed ID: 30555485 [TBL] [Abstract][Full Text] [Related]
18. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer. Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W Front Immunol; 2022; 13():1058424. PubMed ID: 36544779 [TBL] [Abstract][Full Text] [Related]
19. Application of immune checkpoint inhibitors in colorectal cancer. Wang L; Huang C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736 [TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F Front Immunol; 2021; 12():808964. PubMed ID: 35095898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]